tiprankstipranks
Oncolys BioPharma, Inc. (JP:4588)
:4588
Japanese Market

Oncolys BioPharma, Inc. (4588) Price & Analysis

Compare
0 Followers

4588 Stock Chart & Stats


---

Financials

Quarterly

4588 FAQ

What was Oncolys BioPharma, Inc.’s price range in the past 12 months?
Oncolys BioPharma, Inc. lowest stock price was ¥420.00 and its highest was ¥918.00 in the past 12 months.
    What is Oncolys BioPharma, Inc.’s market cap?
    Oncolys BioPharma, Inc.’s market cap is ¥15.78B.
      When is Oncolys BioPharma, Inc.’s upcoming earnings report date?
      Oncolys BioPharma, Inc.’s upcoming earnings report date is May 09, 2025 which is in 39 days.
        How were Oncolys BioPharma, Inc.’s earnings last quarter?
        Oncolys BioPharma, Inc. released its earnings results on Feb 07, 2025. The company reported -¥17.61 earnings per share for the quarter, missing the consensus estimate of N/A by -¥17.61.
          Is Oncolys BioPharma, Inc. overvalued?
          According to Wall Street analysts Oncolys BioPharma, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Oncolys BioPharma, Inc. pay dividends?
            Oncolys BioPharma, Inc. does not currently pay dividends.
            What is Oncolys BioPharma, Inc.’s EPS estimate?
            Oncolys BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Oncolys BioPharma, Inc. have?
            Oncolys BioPharma, Inc. has 24,961,600 shares outstanding.
              What happened to Oncolys BioPharma, Inc.’s price movement after its last earnings report?
              Oncolys BioPharma, Inc. reported an EPS of -¥17.61 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.703%.
                Which hedge fund is a major shareholder of Oncolys BioPharma, Inc.?
                Currently, no hedge funds are holding shares in JP:4588
                ---

                Company Description

                Oncolys BioPharma, Inc.

                Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. Its product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in phase II clinical trial for the treatment of gastric cancer/gastroesophageal junction, head and neck, and esophageal cancers; and in phase I clinical trial for the treatment of hepatocellular carcinoma. The company's product pipeline also includes OBP-702, a telomerase-specific oncolytic adenovirus, which is in pre-clinical trial for the treatment of solid tumors; OBP-2011, which is in pre-clinical trial for the treatment of SARS-Cov-2 virus infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed the phase IIb clinical trial for the treatment of HIV infection; and OBP-801, a histone deacetylase inhibitor, which is in phase I clinical trial for the treatment of solid tumors, as well as in pre-clinical trial for ophthalmic use. In addition, it develops TelomeScan (OBP-401 and OBP-1101), a cancer detection drug, for detecting living circulating tumor cells in blood from cancer patients. Further, the company provides diagnostic drugs and inspection services. It has various licensing agreements with Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Oncolys BioPharma Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Chugai Pharmaceutical Co
                Daiichi Sankyo Company
                Eisai Co
                Otsuka Holdings Co
                NanoCarrier Co., Ltd.
                Popular Stocks
                ---
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis